The global Preimplantation Genetic Testing (PGT) market is experiencing significant growth, driven by increasing awareness and adoption of advanced reproductive technologies. According to a recent report by MarketsandMarkets™, the market, currently valued at US$690.2 million in 2025, is projected to reach a staggering US$1,135.0 million by 2030. This represents a robust Compound Annual Growth Rate (CAGR) of 10.5% over the forecast period.

Preimplantation Genetic Testing is a sophisticated procedure performed on embryos created through in vitro fertilization (IVF) before they are implanted in the uterus. The primary goal of PGT is to screen embryos for genetic abnormalities, such as chromosomal disorders or specific inherited diseases. This allows fertility specialists to select the healthiest embryos for transfer, increasing the chances of a successful pregnancy and reducing the risk of genetic conditions in offspring.

The significant growth in the PGT market can be attributed to several factors. Firstly, there is a rising prevalence of infertility worldwide, leading more couples to seek IVF treatments. As IVF becomes more accessible and accepted, the demand for PGT naturally increases. Secondly, advancements in genetic testing technologies have made PGT more accurate and efficient, boosting its appeal to both patients and clinicians. Furthermore, growing awareness about inherited diseases and the desire to have healthy children are driving the adoption of PGT as a proactive measure.

The MarketsandMarkets™ report highlights the increasing value placed on family planning and proactive healthcare. As genetic screening technologies continue to evolve and become more affordable, the PGT market is expected to maintain its impressive growth trajectory, offering hope and improved outcomes for couples seeking to build healthy families.